ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1252

The Effect of Pretreatment With Resiniferatoxin On Dynamic Weight Bearing Measures and Evoked Pain Responses in An Acute Arthritis Murine Model

Mishal Abdullah1, Christopher W. Dorman2, Sandra Frizelle2, Sonia C. Funkenbusch2, Maren L. Mahowald3 and Hollis E. Krug4, 1Rheumatology, University of Minnesota Medical School, Minneapolis, MN, 2Research, Minneapolis VA Health Care System, Minneapolis, MN, 3Medicine, University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN, 4Medicine, VA Health Care System, Minneapolis, MN

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Mouse model and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pain - Basic Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We have previously shown that activation of vanilloid receptors by intra-articular (IA) Capsaicin (CAP) injection normalizes Evoked Pain Scores (EPS) and Dynamic Weight Bearing (DWB) measures in carrageenan-induced acute inflammatory arthritis. Resiniferatoxin (RTX) is an ultrapotent CAP analogue that has a similar mechanism of action, and may have a greater efficacy on carrageenan-induced arthritis when administered intra-articularly. We hypothesized that mice with acute arthritis would have measurable changes in DWB and EPS due to joint pain, and that these changes could be prevented by pre-treating with IA RTX.

Methods:

C57Bl6 mice were used for all experiments. Acute inflammatory arthritis was produced by IA injection of 10µl of 2.5% carrageenan into the left knee 3 hours prior to pain behavior testing. Two groups of mice were injected with different doses of IA RTX (10µl of 0.001% and 10µl of 0.0003%) 7 days prior to induction of arthritis. Similarly, another group of mice was injected with 10µl of 0.01% IA CAP 7 days prior to induction of arthritis. DWB was measured with a Dynamic Weight Bearing apparatus (Bioseb, Vitrolles, France). Evoked pain behavior was measured by tallying fights + vocalizations/1 min with repeated firm palpation of the knee.

Results:

Arthritis pain can be clearly and reproducibly indicated by increased EPS and reduced DWB measures in the affected limb of arthritic mice. Naïve mice demonstrated low EPS scores (1.01) and equal left to right DWB ratios for weight (1.01) and time (1.00). Induction of acute arthritis by IA Carrageenan resulted in a significantly increased EPS (6.25) and a significant decrease in left to right DWB ratios for weight (0.64) and time (0.89) when compared with controls. Pretreatment with IA CAP 7 days prior to IA Carrageenan resulted in significant improvement in EPS (3.25) and near normalization of left to right DWB ratios for weight (0.975) and time (1.00). Pretreatment with the high dose and the low dose IA RTX 7 days prior to IA Carrageenan lead to significantly improved EPS (1.5 & 1.5, respectively) and left to right DWB ratios for weight (0.85 & 0.82, respectively) and time (0.99 & 0.96, respectively) when compared with the acute arthritis model. IA administration of CAP alone and RTX alone did not have a significant impact on EPS or DWB ratios after 7 days.

Conclusion:

Pain can be quantitated in murine arthritis models using DWB and EPS. IA Carrageenan administration resulted in a significant increase in EPS and a significant decrease in DWB measures in the affected limb. IA RTX pretreatment in these mice clearly improved pain measures as assessed by EPS and DWB measures and these results were comparable to those previously reported for IA CAP. The potential advantages RTX may have over CAP include a possibly lower therapeutic dose and longer duration of effect. These factors represent important directions for future studies.


Disclosure:

M. Abdullah,
None;

C. W. Dorman,
None;

S. Frizelle,
None;

S. C. Funkenbusch,
None;

M. L. Mahowald,
None;

H. E. Krug,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-pretreatment-with-resiniferatoxin-on-dynamic-weight-bearing-measures-and-evoked-pain-responses-in-an-acute-arthritis-murine-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology